| 0 (0%) | 09-27 11:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 144.21 | 1-year : | 151.83 |
| Resists | First : | 123.46 | Second : | 130 |
| Pivot price | 119.31  |
|||
| Supports | First : | 112.9 | Second : | 93.93 |
| MAs | MA(5) : | 117.44  |
MA(20) : | 120.3 |
| MA(100) : | 110.06 |
MA(250) : | 105.74 |
|
| MACD | MACD : | 0.4 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 25 |
D(3) : | 27.8 |
| RSI | RSI(14): 48.5 |
|||
| 52-week | High : | 139.13 | Low : | 75.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AXSM ] has closed above bottom band by 34.4%. Bollinger Bands are 17.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 117.97 - 118.44 | 118.44 - 118.84 |
| Low: | 114.42 - 115 | 115 - 115.5 |
| Close: | 115.76 - 116.7 | 116.7 - 117.52 |
Wed, 24 Sep 2025
Axsome Therapeutics ($AXSM) Is Paying a $7.75M Settlement to Investors — Here’s How to Get Your Shar - TradingView
Tue, 23 Sep 2025
Axsome Therapeutics ($AXSM) $7.75M Investor Settlement - TradingView
Tue, 23 Sep 2025
Axsome Therapeutics (AXSM): Evaluating Valuation After Recent Clinical Data and FDA Update on Pipeline Progress - simplywall.st
Tue, 23 Sep 2025
Axsome Therapeutics and $AXSM Investors Finalise $7.75M Settlement Agreement - TradingView
Tue, 23 Sep 2025
Cantor Fitzgerald Has Weak Forecast for AXSM FY2026 Earnings - MarketBeat
Tue, 23 Sep 2025
Assenagon Asset Management S.A. Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 50 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 15.8 (%) |
| Held by Institutions | 77.5 (%) |
| Shares Short | 3,510 (K) |
| Shares Short P.Month | 3,670 (K) |
| EPS | -5.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.47 |
| Profit Margin | -49.9 % |
| Operating Margin | -29.9 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -280.7 % |
| Qtrly Rev. Growth | 72 % |
| Gross Profit (p.s.) | 9.07 |
| Sales Per Share | 9.92 |
| EBITDA (p.s.) | -4.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -121 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -23.08 |
| PEG Ratio | 0 |
| Price to Book value | 79.42 |
| Price to Sales | 11.76 |
| Price to Cash Flow | -48.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|